0000891293-23-000001.txt : 20230103 0000891293-23-000001.hdr.sgml : 20230103 20230103183652 ACCESSION NUMBER: 0000891293-23-000001 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221229 FILED AS OF DATE: 20230103 DATE AS OF CHANGE: 20230103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KIRSKE DAVID CENTRAL INDEX KEY: 0001276750 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28386 FILM NUMBER: 23503815 MAIL ADDRESS: STREET 1: C/O CTI BIOPHARMA CORP. STREET 2: 3101 WESTERN AVE., SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CTI BIOPHARMA CORP CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2062827100 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: CELL THERAPEUTICS INC DATE OF NAME CHANGE: 19960321 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2022-12-29 0 0000891293 CTI BIOPHARMA CORP CTIC 0001276750 KIRSKE DAVID C/O CTI BIOPHARMA CORP. 3101 WESTERN AVE., SUITE 800 SEATTLE WA 98121 0 1 0 0 EVP, Chief Financial Officer common stock 2022-12-29 4 M 0 13174 0.9489 A 30087 D common stock 2022-12-29 4 S 0 13174 6 D 16913 D common stock 2022-12-30 4 A 0 214 5.1085 A 17127 D common stock 2022-12-30 4 M 0 12000 0.9489 A 29127 D common stock 2022-12-30 4 S 0 12000 6 D 17127 D common stock 2022-12-30 4 M 0 800 0.9489 A 17927 D common stock 2022-12-30 4 S 0 800 6.005 D 17127 D common stock 2022-12-30 4 M 0 1047 0.9489 A 18174 D common stock 2022-12-30 4 S 0 1047 6.01 D 17127 D common stock 2023-01-03 4 M 0 27021 0.9489 A 44148 D common stock 2023-01-03 4 S 0 27021 6.011 D 17127 D Non-Qualified Stock Option (right to buy) 0.9489 2022-12-29 4 M 0 13174 0 D 2029-02-19 Common Stock 13174 311084 D Non-Qualified Stock Option (right to buy) 0.9489 2022-12-30 4 M 0 12000 0 D 2029-02-19 Common Stock 12000 299084 D Non-Qualified Stock Option (right to buy) 0.9489 2022-12-30 4 M 0 800 0 D 2029-02-19 Common Stock 800 298284 D Non-Qualified Stock Option (right to buy) 0.9489 2022-12-30 4 M 0 1047 0 D 2029-02-19 Common Stock 1047 297237 D Non-Qualified Stock Option (right to buy) 0.9489 2023-01-03 4 M 0 27021 0 D 2029-02-19 Common Stock 27021 270216 D This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. David Kirske 2023-01-03